Table 1.
Characteristics of patients hospitalized for COVID-19 by vaccination status.
| Characteristic | Fully Vaccinated | Unvaccinated | p-Value 1 |
|---|---|---|---|
| n = 175 (33.1%) | n = 354 (66.9%) | ||
| Age | 74 (64–83) | 61.5 (48.2–72 | <0.001 |
| Men | 109 (62.3) | 199 (56.2) | 0.191 |
| Charlson index | 4 (3–6) | 2 (1–4) | <0.001 |
| Chronic illnesses 2 | |||
| Cardiovascular disease | 128 (73.1) | 170 (48.0) | <0.001 |
| Pulmonary disease | 35 (20.0) | 32 (9.0) | <0.001 |
| Asthma | 15 (8.6) | 21 (5.9) | – |
| COPD | 19 (10.9) | 11 (3.1) | – |
| Diabetes type II | 62 (35.4) | 51 (14.4) | <0.001 |
| Obesity (body mass index ≥ 30) | 60 (34.3) | 123 (34.7) | 1 |
| Immunocompromising condition 3 | 37 (21.1) | 15 (4.2) | <0.001 |
| One or more comorbidities | 163 (93.1) | 233 (65.8) | <0.001 |
| One comorbidity | 20 (11.4) | 62 (17.5) | – |
| Resident of long-term care facility | 10 (5.7) | 8 (2.3) | 0.071 |
| Vaccine received | |||
| BNT162b2 | 122 (69.7) | – | – |
| ChAdOx-1S | 26 (14.9) | – | – |
| Ad.26.COV2.S | 18 (10.3) | – | – |
| mRNA-1273 | 9 (5.1) | – | – |
| Therapy | |||
| Remdesivir | 21 (12.0) | 34 (9.6) | 0.449 |
| Corticosteroids | 162 (92.6) | 331 (93.5) | 0.715 |
| Dexamethasone | 140 (80.0) | 258 (72.9) | 0.087 |
| Methylprednisolone | 56 (32.0) | 146 (41.2) | 0.046 |
| Tocilizumab | 0 (0) | 14 (4.0) | 0.007 |
| Monoclonal antibodies | 5 (2.9) | 9 (2.5) | 0.782 |
| Hypoxemic at admission | 154 (88.0) | 331 (93.5) | 0.043 |
| Critically severe disease | 33 (18.9) | 92 (26.0) | – |
| (WHO score 7–10) 4 | |||
| Death (WHO score 10) 4 | 24 (13.7) | 46 (13.0) | – |
COPD: Chronic obstructive pulmonary disease. Data are n (%) or median (95% interquartile range). 1 Due to multiple comparisons, p-value < 0.01 was considered significant (marked in bold). 2 See Supplementary Table S1 for definitions of chronic illnesses. 3 Active cancer treatment or newly diagnosed cancer in the past 6 months (n = 24), active hematologic cancer (n = 12), previous solid organ transplant (n = 8), hematopoietic stem cell transplant within the last 2 years (n = 1), active treatment with immunosuppressive medication (n = 7), previous splenectomy (n = 1). One patient had both an hematologic and solid organ cancer. 4 Assessed using the World Health Organization COVID-19 Clinical Progression Scale [21].